Progyny, Inc. (NASDAQ:PGNY) Stake Decreased by SG Americas Securities LLC

SG Americas Securities LLC trimmed its holdings in Progyny, Inc. (NASDAQ:PGNYFree Report) by 33.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,613 shares of the company’s stock after selling 17,539 shares during the quarter. SG Americas Securities LLC’s holdings in Progyny were worth $597,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. Quarry LP grew its stake in shares of Progyny by 1,900.0% in the second quarter. Quarry LP now owns 880 shares of the company’s stock worth $25,000 after purchasing an additional 836 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Progyny by 341.4% in the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock worth $28,000 after purchasing an additional 1,246 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in Progyny in the 2nd quarter valued at about $44,000. Nisa Investment Advisors LLC increased its stake in Progyny by 108.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock valued at $51,000 after buying an additional 1,526 shares during the period. Finally, Mendota Financial Group LLC bought a new stake in shares of Progyny during the 3rd quarter worth about $56,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PGNY has been the topic of a number of research analyst reports. Canaccord Genuity Group lowered their price objective on shares of Progyny from $18.00 to $17.00 and set a “hold” rating on the stock in a research note on Wednesday, November 13th. Truist Financial reiterated a “hold” rating and set a $19.00 price target (down from $26.00) on shares of Progyny in a research report on Wednesday, November 13th. Barclays cut their price objective on Progyny from $30.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. JPMorgan Chase & Co. lifted their target price on Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a report on Tuesday. Finally, Bank of America cut their price target on shares of Progyny from $22.00 to $21.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. Nine analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Progyny has a consensus rating of “Hold” and an average price target of $25.50.

Read Our Latest Stock Analysis on PGNY

Progyny Stock Up 1.2 %

PGNY opened at $23.54 on Friday. The firm has a market capitalization of $2.00 billion, a P/E ratio of 40.59, a PEG ratio of 2.11 and a beta of 1.31. The stock has a fifty day moving average of $17.46 and a 200-day moving average of $19.27. Progyny, Inc. has a 12-month low of $13.39 and a 12-month high of $42.08.

Progyny (NASDAQ:PGNYGet Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.26). The business had revenue of $286.63 million during the quarter, compared to analysts’ expectations of $296.85 million. Progyny had a return on equity of 11.36% and a net margin of 5.03%. The firm’s revenue was up 2.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.16 earnings per share. On average, analysts expect that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Chairman David J. Schlanger purchased 150,000 shares of Progyny stock in a transaction dated Thursday, December 26th. The stock was acquired at an average cost of $14.68 per share, for a total transaction of $2,202,000.00. Following the acquisition, the chairman now directly owns 228,269 shares in the company, valued at $3,350,988.92. This represents a 191.65 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Peter Anevski bought 209,500 shares of Progyny stock in a transaction on Monday, December 23rd. The stock was acquired at an average price of $14.48 per share, with a total value of $3,033,560.00. Following the completion of the purchase, the chief executive officer now directly owns 441,463 shares of the company’s stock, valued at approximately $6,392,384.24. The trade was a 90.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by corporate insiders.

Progyny Company Profile

(Free Report)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Further Reading

Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNYFree Report).

Institutional Ownership by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.